BioNexus Gene Lab Corp. Revenue from Contract with Customer, Including Assessed Tax
BioNexus Gene Lab Corp. (BGLC) reported Revenue from Contract with Customer, Including Assessed Tax of $76.16 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-14
- BioNexus Gene Lab Corp. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $76.16K, a 96.63% decline year-over-year.
- BioNexus Gene Lab Corp. revenue from contract with customer, including assessed tax for the quarter ending 2025-06-30 was $2.26M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month |
|---|---|---|
| 2026-06-30 | $76.16K 10-Q · filed 2026-08-14 | $99.00K 10-Q · filed 2026-08-14 |
| 2025-06-30 | $2.26M 10-Q · filed 2026-08-14 | $4.40M 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |